Safety of micafungin in infants: Insights into optimal dosing

Expert Opinion on Drug Safety

Volumn 10, Issue 2, 2011, Pages 281-286

  Ascher, Simon ^a,b   Smith, Phillip Brian ^a,b   Benjamin Jr , Daniel K ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

adverse effects; drug toxicity; micafungin; premature infants

Indexed keywords

FLUCONAZOLE; MICAFUNGIN;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION PREVENTION; INSOMNIA; INVASIVE CANDIDIASIS; JAW PAIN; NEUTROPENIA; NEWBORN INTENSIVE CARE; PREMATURITY; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT INDICATION; VOMITING;

ADULT; AGE FACTORS; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS, INVASIVE; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHINOCANDINS; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; LIPOPEPTIDES;

EID: 79952326365     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.545345     Document Type: Review

References (39)

1. Benjamin DK Jr, Stoll BJ, Fanaroff AA, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117(1):84-92 (Pubitemid 46050523)
2. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110(2 Pt 1):285-91 (Pubitemid 34833012)
3. Benjamin DK Jr, DeLong ER, Steinbach WJ, et al. Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003;112(3 Pt 1):543-7 (Pubitemid 37082104)
4. Friedman S, Richardson SE, Jacobs SE, et al. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19(6):499-504 (Pubitemid 30409474)
5. Kawaguchi C, Arai I, Yasuhara H, et al. Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int 2009;51(2):220-4
6. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23(12):1093-7 (Pubitemid 40812754)
7. Smith PB, Steinbach WJ, Cotten CM, et al. Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007;27(2):127-9 (Pubitemid 46195914)
8. Wagner C, Graninger W, Presterl E, et al. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78(4):161-77 (Pubitemid 44948055)
9. Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007;48(1):1-12 (Pubitemid 46280129)
10. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9 (Pubitemid 35461658)
11. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82 (Pubitemid 46919773)
12. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44(1):57-62
13. Ikeda F, Wakai Y, Matsumoto S, et al. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000;44(3):614-18 (Pubitemid 30117950)
14. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006;44(2):324-6 (Pubitemid 43222217)
15. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46(1):150-6
16. CLSI. Method for antifungal disk diffusion susceptibility testing of yeasts; approved standard. Document M27-A3. In: Wayne PA, editor, 3rd edition. Clincal and Laboratory Standards Institute; 2008
17. Sakaeda T, Iwaki K, Kakumoto M, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005;57(6):759-64 (Pubitemid 40694884)
18. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16 (Pubitemid 39518200)
19. Hiemenz J, Cagnoni P, Simpson D, et al. Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-6 (Pubitemid 40463357)
20. de Wet N, Llanos-Cuentas A, Suleiman J, et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39(6):842-9 (Pubitemid 39244300)
21. Sirohi B, Powles RL, Chopra R, et al. A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38(1):47-51 (Pubitemid 43923089)
22. Mycamine (package insert). Deerfield, IL: Astellas Pharma; 2005
23. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49(8):3317-24 (Pubitemid 41060577)
24. Kusuki S, Hashii Y, Yoshida H, et al. Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer 2009;53(4):605-9
25. Freire AA, Stevenson P, Undre N. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia [abstract A-772]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17-20 September 2007; Chicago, IL; 2007
26. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25(12):1110-15 (Pubitemid 44900673)
27. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197(1):163-71 (Pubitemid 351263481)
28. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28(5):412-15
29. Kawada M, Fukuoka N, Kondo M, et al. Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J 2009;28(9):840-2
30. Benjamin DK Jr, Smith PB, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87(1):93-9
31. Benjamin DK Jr, Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112(3 Pt 1):634-40 (Pubitemid 37082118)
32. Cohen-Wolkowiez M, Smith PB, Mangum B, et al. Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007;27(2):97-100 (Pubitemid 46195907)
33. Fernandez M, Moylett EH, Noyola DE, et al. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000;31(2):458-63 (Pubitemid 32289576)
34. Mycamine [US Prescribing Information]. Astellas Pharma: Deerfield I, 2008
35. Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010;54(6):2633-7
36. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20(3):153-63 (Pubitemid 36682311)
37. Linder N, Klinger G, Shalit I, et al. Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52(4):663-7 (Pubitemid 37258429)
38. Scarcella A, Pasquariello MB, Giugliano B, et al. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17(2):146-8 (Pubitemid 28096014)
39. Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009;29(11):738-43